Comparative Pharmacology
Head-to-head clinical analysis: PCE versus WYAMYCIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PCE versus WYAMYCIN S.
PCE vs WYAMYCIN S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PCE (erythromycin) binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptides.
WYAMYCIN S (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Erythromycin ethylsuccinate (PCE) typical adult dose: 400 mg orally every 6 hours or 800 mg orally every 12 hours. Maximum 4 g/day.
WYAMYCIN S (clarithromycin/sulfamethoxazole) is a fixed-dose combination. Adult: 1 tablet (500 mg clarithromycin/800 mg sulfamethoxazole) orally every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to 7-10 hours in renal impairment (CrCl <30 mL/min).
2-3 hours in normal renal function; prolonged to 24-48 hours in end-stage renal disease.
Primarily renal (about 70-80% as unchanged drug and metabolites via glomerular filtration and tubular secretion); minor biliary/fecal elimination (10-15%).
Renal (90-95% unchanged via glomerular filtration) and biliary (<5%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic